title: Lipid intolerance in newborns is associated with hepatic dysfunction but not infection.
abstract: OBJECTIVE
  To examine the hypothesis that fat intolerance in newborns who receive intravenous lipid is related to both infection and liver dysfunction.
  
  
  METHODS
  Prospective survey.
  
  
  METHODS
  Tertiary intensive care nursery.
  
  
  METHODS
  All newborns who were admitted to the neonatal intensive care unit during a 20-month period and received parenteral lipid for 2 or more weeks were eligible for the study. Of 279 newborns who received parenteral nutrition, 162 met eligibility criteria and form the basis of this report.
  
  
  METHODS
  None.
  
  
  METHODS
  Fat intolerance as defined by a serum triglyceride level of 1.69 mmol/L or greater (> or = 150 mg/dL).
  
  
  RESULTS
  Triglyceride levels were similar in infected and noninfected patients. Newborns with hypertriglyceridemia were more likely to have liver dysfunction (P < .001) or growth retardation (P < .01), but not infections. Hypertriglyceridemia was approximately twice as likely (P < .05) in newborns with either growth retardation or liver dysfunction.
  
  
  CONCLUSIONS
  Liver dysfunction and fetal growth retardation were associated with lipid intolerance in newborns who received intravenous fat. Infection does not appear to be independently associated with hypertriglyceridemia. In the absence of liver dysfunction or growth retardation, there is no a priori reason to limit intravenous lipid use in the presence of infection. Close monitoring of triglyceride levels with adjustments in lipid dose is warranted, especially in small, sick newborns who are at highest risk for hypertriglyceridemia.
authors.affiliation: Department of Pediatrics and Adolescent Medicine, St Louis, University School of Medicine, Mo, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Toce
authors.forename: W J
authors.initials: WJ
authors.lastname: Keenan
mesh_terms: D000075202:Contraindications; D005217:Fat Emulsions, Intravenous / Q000009:adverse effects*; D005317:Fetal Growth Retardation / Q000209:etiology; D006801:Humans; D015228:Hypertriglyceridemia / Q000209:etiology*; D007227:Infant Nutritional Physiological Phenomena; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D008099:Liver / Q000503:physiopathology; D008107:Liver Diseases / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D010288:Parenteral Nutrition; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: D005217:Fat Emulsions, Intravenous; D014280:Triglycerides